New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period
Nerviano, 1 February 2024 The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 000 international patent families (IPFs) have been registered by Italian companies and research facilities. Among them, Nerviano Medical Sciences stands out as the top applicant during the 2002-2021 period.
We are proud of this finding that testifies to our commitment to be at the forefront of innovation in oncology through research and development of small molecules and new payload-linkers, bringing innovative therapies to those who need them most.
Link ITA: Comunicato Stampa
Link ENG: Press Release
from NMSGroup
